FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No

(MedPage Today) — The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market…

Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/119741

Author :

Publish date : 2026-02-04 21:29:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No

Particle Pollution From Wildfire Smoke Tied to 24,000 U.S. Deaths Each Year

‘Most Compelling’ Data Yet for Metastasis-Directed Therapy in Prostate Cancer

Related Posts

Autism Panel Targets RFK Jr.’s Agenda

HPV Self-Testing in Primary Care Boosts Cervical Cancer Screening

It Was a Rough Match Day for Family Medicine, IMGs

Study Warns on High-Risk Group After Stool-Based Colon Cancer Screening

Match Day 2026: Is Family Medicine Half-Full or Half-Empty?

Victoria Pilots PA Program for Harm Reduction Workers

Autism Panel Targets RFK Jr.’s Agenda

HPV Self-Testing in Primary Care Boosts Cervical Cancer Screening

It Was a Rough Match Day for Family Medicine, IMGs

Study Warns on High-Risk Group After Stool-Based Colon Cancer Screening

Match Day 2026: Is Family Medicine Half-Full or Half-Empty?

Victoria Pilots PA Program for Harm Reduction Workers

Match Day Joy: Today Is the Day for Thousands of Students

Next-Gen Nerve Stimulator Approved for Obstructive Sleep Apnea

Categories

Archives